Avid Bioservices Inc (CDMO)

[mojojojo]

There were only a modest number of PS=2 though, so this is not a large effect on what an expected median would be.

Here's what I'm seeing regarding this. I would agree that the combined arm of the phase 2 trial had a modest amount of ECOG status 2 patients with 12.5% but the bavi 3 mg/kg arm had almost double that with 24.4%. Because it's been shown that NSCLC ECOG status 2 patients end up with dramatically smaller MOS results compared to ECOG status 0 and 1 patients, it seems likely that for the phase 2 trial, the MOS for the bavi 3 mg/kg arm got dragged down because of the disproportional amount of these sicker patients.